AstellasSeattle Genetics target advanced bladder cancer with enfortumab vedotin

Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotin

Roche and Merck & Co have got their respective immunotherapies Tecentriq and Keytruda approved in bladder cancer – but the problem of low response rates remains. At the ASCO annual conference in Chicago researchers highlighted that the respons...

More From BioPortfolio on "Astellas/Seattle Genetics target advanced bladder cancer with enfortumab vedotin"